Pacira Pharmaceuticals Recalls 40,517 Zilretta Kits Over Failed Dissolution Specifications
Pacira Pharmaceuticals, Inc. has initiated a Class II recall for 40,517 kits of Zilretta (triamcinolone acetonide extended-release injectable suspension) due to failed dissolution specifications. This voluntary, firm-initiated action impacts US nationwide distribution, necessitating immediate review of inventory and potential supply chain adjustments for buyers of intra-articular corticosteroids.
FDA Class II Recall: Pacira's Zilretta Fails Dissolution Specifications
Pacira Pharmaceuticals, Inc. has initiated a voluntary, firm-initiated Class II recall for its product, Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, under recall number D-0567-2024. This action, initiated on June 12, 2024, stems from the product's failure to meet dissolution specifications. Specifically, the affected lot did not satisfy the acceptance criteria for IVR Level 3 testing after 9 months of storage at 2-8°C, followed by an additional 6 weeks at 25°C. For procurement directors, this failure signals a critical quality control lapse, potentially impacting product efficacy and patient outcomes. A Class II classification indicates that the use of the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This means that while immediate severe harm is unlikely, the inconsistent release of the active pharmaceutical ingredient, triamcinolone acetonide, could lead to suboptimal therapeutic effects for patients relying on Zilretta for sustained pain relief. Business development executives should recognize the potential for reputational damage to Pacira and the broader implications for market confidence in extended-release formulations.
Product and Company Profile: Pacira Pharmaceuticals' Recalled Intra-Articular Suspension
The recalled product, Zilretta, is a human prescription drug administered via intra-articular route, indicated for pain management. Manufactured for Pacira Pharmaceuticals, Inc., located in San Diego, CA, the product holds NDA208845 and is identified by NDCs 65250-003-01 (carton), 65250-001-01 (vial), and 65250-002-01 (diluent vial). The specific lot affected by this recall is Lot 23-9006, with an expiry date of March 2025. A substantial quantity of 40,517 kits has been distributed US nationwide. For regulatory affairs heads, this detailed product information is crucial for accurately assessing the scope of the recall and ensuring all necessary internal and external communications are compliant. Supply chain VPs must immediately identify if their organizations have procured this specific lot, as the recall necessitates removal from distribution channels. The significant quantity of recalled kits underscores the potential for widespread impact across the US healthcare system, requiring prompt action to prevent further use of the non-compliant product and to manage inventory effectively.
Supply Chain Disruption and Market Repercussions for Triamcinolone Acetonide
The US nationwide distribution of 40,517 kits of Zilretta Lot 23-9006 presents a tangible supply chain disruption for healthcare providers and patients relying on triamcinolone acetonide extended-release injectable suspension. Procurement directors must swiftly assess their current inventory levels and identify any affected units to prevent their use. The Class II nature of this recall, indicating potential for medically reversible adverse health consequences, means that healthcare systems may need to seek alternative treatments or formulations for patients who would have received Zilretta. This sudden withdrawal of a significant product quantity can create immediate demand shifts for competing intra-articular corticosteroid products. Business development executives should monitor these market dynamics closely, as competitors may see increased demand. Furthermore, the recall could lead to increased scrutiny from payers regarding the quality and reliability of extended-release injectable suspensions, potentially influencing future formulary decisions and procurement strategies for similar products.
Regulatory Compliance Imperatives: Dissolution Testing and Industry Vigilance
This recall by Pacira Pharmaceuticals highlights the critical importance of robust dissolution testing, particularly for extended-release drug products like Zilretta. Dissolution specifications ensure that the active pharmaceutical ingredient, triamcinolone acetonide, is released consistently over time, which is fundamental to the product's therapeutic claims and patient safety. A failure in this area, especially under specified storage conditions, indicates a potential instability issue that could compromise the drug's intended action. For regulatory affairs heads, this incident reinforces the need for rigorous quality management systems and continuous stability monitoring programs. The broader regulatory landscape, as evidenced by recent parallel events such as Essential Wellness Pharma's Class II recall for progesterone injection due to sterility failure and an FDA hearing impacting Amgen's Tavneos, demonstrates ongoing heightened scrutiny from the FDA. These events collectively underscore that pharmaceutical companies must maintain unwavering vigilance in all aspects of manufacturing and quality control to mitigate compliance risks and safeguard product integrity.
Pacira's Remediation Path and Future Supply Outlook
The recall of Zilretta is currently categorized as 'Ongoing,' indicating that Pacira Pharmaceuticals, Inc. is actively managing the process. As a voluntary, firm-initiated recall, Pacira is expected to conduct a thorough root cause investigation into the dissolution failure, implement comprehensive corrective and preventive actions (CAPA), and ensure all future batches of triamcinolone acetonide extended-release injectable suspension meet stringent quality specifications. For supply chain VPs, monitoring Pacira's remediation progress is crucial for forecasting long-term supply stability. Any delays or further quality issues could prolong market disruption and necessitate more permanent sourcing adjustments. While the immediate impact is a Class II recall, failure to adequately address the underlying quality system deficiencies could lead to escalated FDA enforcement actions in the future. Procurement directors should maintain open communication with Pacira to understand their remediation timeline and assess the reliability of future product supply, ensuring business continuity for their organizations and uninterrupted patient access to necessary treatments.